Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLD-103 in Basal Cell Carcinoma
NCT07670858Phase 1Completed
- Sponsor
- Feldan Therapeutics
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Countries
- 2
01
Overview
Phase 1, open-label trial of FLD-103 in basal cell carcinoma (BCC) (9 arms), sponsored by Feldan Therapeutics. Primary endpoints: Treatment Emergent Adverse Events and Local Skin Response. Started Oct 2024; status: completed.
02
Drugs
FLD-103
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT07670858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670858.